Cartilage Regeneration: New Drug Reverses Knee Damage in Mice & Shows Promise for Humans

The promise of regenerating damaged cartilage, and potentially halting the progression of osteoarthritis, has moved closer to reality thanks to research led by scientists at Stanford Medicine. A new study demonstrates that blocking a protein linked to aging can reverse cartilage loss in aging mice and even prevent arthritis following knee injuries. The findings, published in Science, suggest a potential path toward treatments – perhaps even an oral medication – that could reduce or eliminate the need for joint replacement surgery, a procedure affecting hundreds of thousands of people annually.

Understanding Osteoarthritis and Its Impact

Osteoarthritis, a degenerative joint disease, affects roughly one in five adults in the United States, translating to over 50 million people, and carries an estimated $65 billion annual price tag in direct healthcare costs. Current treatments primarily focus on managing pain and symptoms, or ultimately replacing the damaged joint with metal and plastic prosthetics. Crucially, Notice currently no approved therapies capable of slowing down or reversing the underlying cartilage damage. This new research targets the root cause of the disease, offering a fundamentally different approach.

The study centers on a protein called 15-PGDH, which researchers have termed a “gerozyme” – an enzyme whose levels increase with age and contribute to tissue dysfunction. Identified in 2023 by the same Stanford team, gerozymes are now understood to play a significant role in age-related loss of muscle strength and other tissue deterioration. Blocking 15-PGDH in mice has previously been shown to increase muscle mass and endurance, while conversely, increasing its production in young mice leads to muscle weakening.

A Novel Mechanism of Cartilage Regeneration

What sets this research apart is the discovery of how cartilage regeneration occurs. Unlike many other tissues, cartilage doesn’t appear to rely on stem cells for repair. Instead, the study found that blocking 15-PGDH causes existing cartilage cells, called chondrocytes, to shift into a more youthful state, altering their gene expression patterns. Specifically, the proportion of chondrocytes producing inflammatory molecules and cartilage-degrading enzymes decreased, while those expressing genes associated with healthy cartilage formation increased. “What we have is a new way of regenerating adult tissue, and it has significant clinical promise for treating arthritis due to aging or injury,” explained Helen Blau, PhD, professor of microbiology and immunology at Stanford Medicine.

The researchers observed dramatic cartilage regeneration in older mice after injecting them with a small molecule inhibitor of 15-PGDH, both systemically (throughout the body) and directly into the knee joint. The regenerated tissue was confirmed to be hyaline cartilage – the smooth, glossy cartilage that allows for low-friction joint movement – rather than the less functional fibrocartilage.

Protecting Against Injury-Induced Arthritis

The benefits extended beyond simply reversing age-related cartilage loss. The treatment also proved protective against arthritis development in mice that sustained knee injuries mimicking ACL tears, a common sports injury. Mice receiving the 15-PGDH inhibitor were significantly less likely to develop osteoarthritis following the injury, and demonstrated improved movement and weight-bearing capacity compared to untreated animals. This is particularly significant given that approximately half of individuals who experience an ACL tear will develop osteoarthritis within 15 years. The research builds on prior perform identifying signs of aging in knee function and cartilage.

Human Tissue Shows Promise

Perhaps most encouragingly, the treatment also showed positive effects on human cartilage samples obtained from patients undergoing total knee replacement surgery. After just one week of exposure to the 15-PGDH inhibitor, the human tissue exhibited reduced levels of 15-PGDH-producing chondrocytes, decreased expression of cartilage degradation genes, and early signs of articular cartilage regeneration. “The mechanism is quite striking and really shifted our perspective about how tissue regeneration can occur,” said Nidhi Bhutani, PhD, associate professor of orthopaedic surgery.

The Role of Prostaglandin E2

The research builds on previous findings from Dr. Blau’s lab demonstrating the importance of prostaglandin E2 in muscle stem cell function. 15-PGDH breaks down prostaglandin E2, and blocking 15-PGDH or increasing prostaglandin E2 levels has previously been shown to promote tissue repair in muscle, nerve, bone, and other tissues. This led the team to investigate whether a similar pathway was involved in cartilage aging and joint damage. They discovered that 15-PGDH levels roughly doubled in knee cartilage as mice aged.

What Comes Next: From Bench to Bedside

An oral version of the 15-PGDH inhibitor is already undergoing clinical trials to assess its effectiveness in treating age-related muscle weakness. Researchers are optimistic that a similar trial will soon be launched to evaluate its potential for cartilage regeneration. Phase 1 trials of the inhibitor for muscle weakness have already demonstrated its safety and activity in healthy volunteers. The team emphasizes the potential to not only halt the progression of osteoarthritis but to actually reverse existing cartilage damage, potentially avoiding the need for joint replacement surgery altogether.

While the findings are promising, it’s important to note that this research is still in its early stages. Further studies are needed to confirm the efficacy and safety of the treatment in humans, and to determine the optimal dosage and delivery method. However, this work represents a significant step forward in the quest to develop effective therapies for osteoarthritis and other age-related joint conditions.